Yahoo
NasdaqCM - Nasdaq Real Time Price USD

GRI Bio, Inc. (GRI)

1.9250 -0.3850 (-16.78%)
As of 10:54:16 AM EDT. Market Open.
Chart Range Bar
Loading chart for GRI
  • Previous Close 2.3100
  • Open 2.1100
  • Bid 2.2200 x 100
  • Ask 2.2800 x 100
  • Day's Range 1.8100 - 2.1500
  • 52 Week Range 1.8100 - 80.3600
  • Volume 482,611
  • Avg. Volume 92,142
  • Market Cap (intraday) 3.409M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 0.05
  • EPS (TTM) 38.8900
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 21.00

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

www.gribio.com

3

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GRI
72.17%
S&P 500 (^GSPC)
9.51%

1-Year Return

GRI
95.09%
S&P 500 (^GSPC)
25.34%

3-Year Return

GRI
100.00%
S&P 500 (^GSPC)
70.00%

5-Year Return

GRI
100.00%
S&P 500 (^GSPC)
79.92%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -2M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-3M
-2M
-1M
0

Analyst Insights

View More

Analyst Price Targets

10.00
21.00 Average
1.9250 Current
32.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/1/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 40 -> 32

Statistics

View More

Valuation Measures

Annual
As of 6/17/2026
  • Market Cap

    4.11M

  • Enterprise Value

    -6.88M

  • Trailing P/E

    0.06

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.39

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -88.82%

  • Return on Equity (ttm)

    -185.67%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.91M

  • Diluted EPS (ttm)

    38.8900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.05M

  • Total Debt/Equity (mrq)

    0.55%

  • Levered Free Cash Flow (ttm)

    -7.61M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.9250 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: